Please assess the completion status of the following clinical trial:

Trial Title: The Estrogen Impact on Overactive Bladder Syndrome: Female Pelvic Floor Microbiomes and Antimicrobial Peptides

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Overactive bladder~* Clinical diagnosis of Postmenopausal:~* English language skills sufficient to complete questionnaires~* Clinical indication for vaginal estrogen use~* Not currently receiving vaginal estrogen therapy~Exclusion Criteria:~* Currently on systemic hormone replacement therapy (HRT) Have been on HRT within the past three months~* Clinical diagnosis of estrogen dependent malignancies~* Allergy to local estrogen therapy~* Insufficient language skills to complete study questionnaires~* Women with active, urinary tract infection~* Received antibiotics within the past two weeks~* Clinical diagnosis of stage 3 or 4 pelvic organ prolapse~* Patient unwilling to use vaginal estrogen preparation~* Currently on anticholinergic medication Have received anticholinergic medication within the past three months~* Previously failed two medications for treatment of OAB Previously received intra-vesicle botulinum toxin injections Previously had posterior tibial nerve stimulation Previously had implantation of sacral neuromodulator~* Patients wishing to start anticholinergic medication at the initial encounter~* Undiagnosed abnormal genital bleeding~* Clinical diagnosis of deep vein thrombosis (DVT) Clinical diagnosis of pulmonary embolism (PE)~* Clinical diagnosis of arterial thromboembolic disease~* Clinical diagnosis of liver dysfunction or disease~* Clinical diagnosis of protein C, protein S or antithrombin or deficiency other known thrombophilic disorders

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- conjugated estrogen (Type: OTHER): All patients in the study will receive 0.625 mg conjugated estrogen/gram to use 0.5 grams twice weekly with the applicator for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).